Phase 2
N=13
Treatment for Calcium Phosphate Kidney Stone Disease
Calcium Phosphate Kidney Stones
Bottom Line
View on ClinicalTrials.gov: NCT01754779 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Placebo (Dietary_supplement); Citric Acid (Dietary_supplement); Potassium Citrate (Dietary_supplement)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of Texas Southwestern Medical Center
- Primary completion
- Feb 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Urinary Calcium Phosphate Saturation |
2.38; 1.97; 2.19 | — |
Summary
The investigators will examine in two studies whether citric acid or potassium citrate can reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers.
Eligibility Criteria
Inclusion Criteria
Aim 1
- Hypocitraturic CaP stone formers
- urine citrate 21 years
Aim 2
- Hypercalciuric CaP stone formers
- 24hr urine calcium >250mg/d in women and >300mg/d in men prior to indapamide use
- high pH as >6.40 in the absence of urinary tract infection
- >21 years
Data sourced from ClinicalTrials.gov (NCT01754779). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.